BioMarin (BMRN) Secured 20% U.S. Royalties on Yuviwel. Is Monetizing a Rival Better than Blocking It?
BioMarin (BMRN) settled a patent dispute with Ascendis Pharma (ASND), securing 20% U.S. royalties on Yuviwel sales. The deal resolves litigation and grants BioMarin royalties on Yuviwel's net sales in several markets through 2030. Yuviwel's growth could impact BioMarin's Voxzogo sales, creating both opportunities and risks.
How this was made
The 30-second read
Why it matters
The settlement removes litigation risk and creates a new revenue stream for BioMarin while imposing a royalty cost on Ascendis, potentially reshaping competitive dynamics with BioMarin's own product Voxzogo.
Market read
The deal introduces a novel royalty model in the rare‑disease space, affecting earnings expectations for both parties and their competitors.
What to watch
Potential future indications for Yuviwel could extend royalty benefits beyond 2030, and pricing dynamics may affect royalty magnitude.
Background
BioMarin resolved a global patent dispute with Ascendis by converting it into a royalty‑bearing license for the achondroplasia drug Yuviwel.
Ticker impact
BioMarin will receive a 20% royalty on U.S. Yuviwel net sales, creating a new revenue stream and offsetting litigation costs.
Modest upside potential if Yuviwel sales grow; limited downside as royalties are capped and time‑bound.
Royalties are retroactive and tied to Yuviwel performance; the deal removes litigation risk but also cedes future blocking leverage.
Ascendis will pay BioMarin royalties on Yuviwel sales, linking its future cash flow to the settlement.
Potential slight pressure on share price due to the royalty burden, offset by avoiding legal costs.
The royalty expense is limited in duration (until May 2030) and applies only to certain markets, so impact is bounded.
Market effects
Sets a precedent for royalty‑based settlements in rare‑disease biotech, influencing valuation of similar pipeline assets.
Impacts U.S., EU, Brazil and South Korea markets where Yuviwel will be sold.
Highlights competitive dynamics between rare‑disease therapies worldwide.
Counterpoint
The royalty may undervalue BioMarin's patents; a direct acquisition of Yuviwel could have yielded greater upside.
Key entities
- companyBioMarin Pharmaceutical Inc.
US‑listed biotech receiving royalties.
- companyAscendis Pharma A/S
Danish biotech paying royalties.
